作者: SEBASTIAO A. P. SAMPAIO
DOI: 10.1001/ARCHDERM.1960.01580040145026
关键词: Leishmania braziliensis 、 Medicine 、 Amphotericin B 、 Paracoccidioidomycosis 、 Prednisone 、 Immunology 、 Stibophen 、 Dermatology 、 Mucocutaneous zone 、 Arsphenamine 、 Leishmaniasis
摘要: Since amphotericin B was isolated in 1955 by Gold, Stout, Pagano, and Donovick,1 numerous papers have reported its beneficial effect the treatment of systemic mycoses, 2-7 including South American blastomycosis.8-10 (mucocutaneous) leishmaniasis still constitutes a serious problem certain areas Brazil Latin America, mucous membrane involvement requiring intensive treatment. On other hand, there is occurrence frequent cases relapses resistance to usual therapy. For these reasons unexpected effectiveness new hope for patients suffering from this disease. The usefulness drug disease verified simultaneously Furtado 11 Lacaz et al., 12 four three patients, respectively. clinical results were confirmed with vitro studies Silva, 13 who inhibitory against leptomonas cultures Leishmania braziliensis